[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360841-105":59,"doc-detail-360841-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-evolving-pi-rads-paradigm","The evolving PI-RADS paradigm","","Prostate MRI is central to the diagnostic pathway for prostate cancer (PCa), reducing unnecessary biopsies, improving the detection of clinically significant disease (csPCa), and limiting overdiagnosis of indolent tumours. The Prostate Imaging Reporting and Data System (PI-RADS) v2.1 is the current international standard for MRI acquisition and interpretation. This review synthesises evidence on PI-RADS strengths, limitations, and future developments, highlighting remaining gaps in image-quality variability, non-diagnostic scan exclusion, lesion scoring challenges (notably PI-RADS 3), measurement standards, and guidance for central-zone and atypical lesions.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-evolving-pi-rads-paradigm/360841/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-evolving-pi-rads-paradigm/360841.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the purpose of PI-RADS in prostate MRI?","Question",{"text":113,"@type":114},"PI-RADS standardizes interpretation and reporting within the prostate cancer diagnostic pathway, improving reproducibility and guiding clinical decisions such as biopsy strategies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which limitations of PI-RADS are highlighted in the review?",{"text":118,"@type":114},"The review notes substantial variability in MRI image quality across centres, an absence of mechanisms to exclude non-diagnostic scans, and ongoing scoring challenges including ambiguous management of PI-RADS 3 lesions and limited guidance for specific lesion types.",{"name":120,"@type":111,"acceptedAnswer":121},"How can artificial intelligence support PI-RADS implementation?",{"text":122,"@type":114},"Artificial intelligence may reduce variability, improve lesion detection, and optimize workflow, but it requires rigorous validation and clear frameworks for integrating human and AI assessment.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},360841,1790193219,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Ponsiglione etal. Cancer Imaging (2026) 26:86 Cancer Imaging  \n[https://doi.org/10.1186/s40644-026-01035-7](https://doi.org/10.1186/s40644-026-01035-7)  \nREVIEW Open Access  \nThe evolving PI-RADS paradigm  \nAndrea Ponsiglione 1, Ivo G. Schoots2,3 and Anwar R. Padhani4*  \nAbstract  \nProstate MRI is central to the diagnostic pathway for prostate cancer (PCa), reducing unnecessary biopsies, improving the detection of clinically significant disease (csPCa), and limiting overdiagnosis of indolent tumours. The Prostate Imaging Reporting and Data System (PIRADS) version 2.1 is the current international standard for MRI data acquisition and interpretation. This review synthesises the evidence for its use, its strengths and limitations, and future developments. PI-RADS v2 .1 improved the assessments of multiparametric MRI (mpMRI) by clarifying technical requirements, zone-specific interpretation rules, and structured reporting recommendations. Its diagnostic performance is well established, particularly for ruling out csPCa and guiding risk-adapted biopsy strategies. However, significant gaps remain. MRI image quality varies substantially across centres, and PI-RADS lacksa mechanism to exclude non-diagnostic scans, resulting in inconsistent classification. Several scoring challenges persist, most notably the ambiguous definition and heterogeneous management of PI-RADS 3 lesions, imprecise lesion measurement standards, and limited guidance for central-zone and atypical lesions. Gaps include the absence of strategies for assessing background tissue changes and infiltrative patterns. Cancer detection specificity and inter-reader agreement remain moderate, with significant discrepancies in transition-zone assessments.  \nArtificial intelligence (AI) holds promise for reducing variability, improving lesion detection, and optimising workflow, though rigorous validation and clear human-AI integration frameworks are needed. Advances in deep learning reconstructions improve image quality and enable shorter protocols, thereby supporting the adoption of biparametric MRI. A shift toward risk-based pathways, integrating MRI findings with PSA density and clinical parameters, is reflected in the forthcoming PI-RADS Pathway 2026, which aims to standardize global biopsy practice and reduce unnecessary interventions.  \nKeywords Prostate cancer, MRI, PI-RADS, Challenges, Artificial intelligence, Diagnostic pathways  \n*Correspondence:  \nAnwar R. Padhani  \n[anwar.padhani@stricklandscanner.org.uk](anwar.padhani@stricklandscanner.org.uk)  \n1Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy  \n2Department of Radiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands  \n3Department of Radiology and Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands  \n4Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK  \nIntroduction  \nMagnetic resonance imaging (MRI) has become the cornerstone of the diagnostic pathway for prostate cancer (PCa), serving as the preferred imaging modality for men with a clinical suspicion of disease [1]. Incorporating MRI upfront into the diagnostic pathway before a biopsy reduces unnecessary biopsies, enhances the detection of clinically significant PCa (csPCa), and limits the overdiagnosis of indolent tumours [2, 3]. For these reasons, current international guidelines recommend MRI as the triage test for symptomatic or asymptomatic men, with alife expectancy of 10–15 years in a shared decision-making paradigm [4]. Eligible patients include average-risk  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, an","cbCait8RPZU7UJXq","https://ap.wps.com/l/cbCait8RPZU7UJXq","pdf",1396599,12,"English","# Abstract\n# Introduction\n## MRI in the diagnostic pathway for prostate cancer\n## Role of PI-RADS and its revisions\n# PI-RADS v2.1: strengths, limitations, and future directions","[{\"question\":\"What is the purpose of PI-RADS in prostate MRI?\",\"answer\":\"PI-RADS standardizes interpretation and reporting within the prostate cancer diagnostic pathway, improving reproducibility and guiding clinical decisions such as biopsy strategies.\"},{\"question\":\"Which limitations of PI-RADS are highlighted in the review?\",\"answer\":\"The review notes substantial variability in MRI image quality across centres, an absence of mechanisms to exclude non-diagnostic scans, and ongoing scoring challenges including ambiguous management of PI-RADS 3 lesions and limited guidance for specific lesion types.\"},{\"question\":\"How can artificial intelligence support PI-RADS implementation?\",\"answer\":\"Artificial intelligence may reduce variability, improve lesion detection, and optimize workflow, but it requires rigorous validation and clear frameworks for integrating human and AI assessment.\"}]","The evolving PI-RADS paradigm | PDF",1790141777]